Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.36 |
| ▸ | EED | O75530 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 7/20 | 0.33 |
| ▸ | HTR2A | P28223 | 6/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | HTR6 | P50406 | 1/20 | 0.33 |
| ▸ | PRKCI | P41743 | 1/20 | 0.32 |
| ▸ | MET | P08581 | 2/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.31 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL599047 | 0.78 | HTR2A (0.53) | BRD4CREBBPHTR2CHTR2ACYP2A6 | |
| SCHEMBL30861517 | 0.77 | HTR2A (0.54) | BRD4CREBBPHTR2CHTR2ACYP2A6 | |
| SCHEMBL21244767 | 0.77 | KDM4E (0.39) | BRD4CREBBPHTR2CHTR2ACYP2A6 | |
| SCHEMBL15712255 | 0.77 | HTR2A (0.54) | BRD4CREBBPHTR2CHTR2ACYP2A6 | |
| SCHEMBL8768621 | 0.77 | BRD4 (0.36) | BRD4CREBBPHTR2CHTR2ACYP2A6 | |
| SCHEMBL598834 | 0.77 | HTR2A (0.54) | BRD4CREBBPHTR2CHTR2ACYP2A6 | |
| SCHEMBL21244778 | 0.77 | BRD4 (0.36) | BRD4CREBBPEEDHTR2CHTR2A | |
| SCHEMBL19538885 | 0.76 | AKR1C3 (0.40) | BRD4CREBBPEEDHTR2CHTR2A | |
| SCHEMBL4399850 | 0.74 | HTR2C (0.43) | BRD4CREBBPHTR2CHTR2AHTR6 | |
| SCHEMBL597518 | 0.74 | HTR2C (0.58) | HTR2CCYP2A6HTR6SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190192697-A1 | CHEMICAL PROBES OF LYSYL OXIDASK-LIKE 2 AND USES THEREOF | PHARMAKEA, INC. | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190192697-A1 | CHEMICAL PROBES OF LYSYL OXIDASK-LIKE 2 AND USES THEREOF | LOXL2, LOXL1, LOXL3 | BRD4 2357/4885CREBBP 3030/4885EED 4535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.